Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of “Hold” from Analysts

Shares of Pfizer Inc. (NYSE:PFE) have received a consensus rating of “Hold” from the twenty-three brokerages that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $28.0476.

Several equities analysts recently issued reports on PFE shares. TD Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Monday. Royal Bank Of Canada started coverage on shares of Pfizer in a report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price objective on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Finally, Barclays started coverage on Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target for the company.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: PF-07328948 kidney-function Phase 1 progress — Pfizer updated an ongoing study that management says supports long‑term pipeline value, reinforcing future R&D upside. Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value
• Positive Sentiment: Oncology milestones broaden non‑COVID revenue path — Phase 3 PADCEV + Keytruda data and a full FDA approval for a BRAFTOVI regimen are material near‑term clinical wins that boost recurring oncology revenue prospects. Pfizer Oncology Milestones Reshape Outlook Beyond COVID 19 Revenues
• Positive Sentiment: Dividend/defensive narrative supports demand — MarketBeat highlights Pfizer’s 6%+ yield and defensive appeal amid volatility, which can attract income‑seeking flows into PFE. The Dividend Safe Harbor: 2 Stocks to Watch
• Positive Sentiment: Analyst upgrade — Argus raised Pfizer to Buy with a $35 target, signaling upside from current levels and likely supporting positioning by discretionary investors. Benzinga coverage of Argus upgrade
• Neutral Sentiment: AI adoption in manufacturing — A market report cites Pfizer among majors integrating AI (predictive maintenance, quality control). It’s a positive long‑term efficiency story but not an immediate revenue catalyst. AI in Pharma Manufacturing Market Research 2026-2040
• Neutral Sentiment: “Quiet cash comeback” narrative — Commentary on improving cash generation supports the valuation case, but it’s an incremental theme rather than a single price mover. Pfizer’s Quiet Cash Comeback
• Negative Sentiment: Zumrad EMA filing withdrawn — Pfizer pulled its Zumrad application in Europe, a clear regulatory setback that removes a near‑term approval pathway and can pressure sentiment. Pfizer withdraws Zumrad EMA filing
• Negative Sentiment: CEO flags issues with FDA vaccine leadership — Public criticism of the FDA’s vaccine leadership introduces regulatory uncertainty and could complicate future review processes or timelines. Pfizer CEO flags issues with FDA’s vaccine leadership

Pfizer Trading Down 2.4%

Shares of PFE stock opened at $26.60 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock’s 50 day simple moving average is $26.20 and its two-hundred day simple moving average is $25.44. The company has a market cap of $151.25 billion, a PE ratio of 19.56 and a beta of 0.47. Pfizer has a 1 year low of $20.92 and a 1 year high of $27.94.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the prior year, the business posted $0.63 earnings per share. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. Research analysts predict that Pfizer will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is 126.47%.

Institutional Trading of Pfizer

Hedge funds and other institutional investors have recently modified their holdings of the business. Fiduciary Alliance LLC increased its holdings in shares of Pfizer by 46.4% in the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after purchasing an additional 46,043 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in Pfizer in the 3rd quarter valued at $3,019,000. Money Concepts Capital Corp raised its position in Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after buying an additional 57,188 shares during the last quarter. Vista Investment Partners LLC raised its position in Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after buying an additional 48,900 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. boosted its holdings in shares of Pfizer by 76.4% in the third quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after acquiring an additional 47,319 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.